MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Aldeyra Therapeutics Inc

Fermé

1.4 -73.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.18

Max

5.32

Chiffres clés

By Trading Economics

Revenu

-696K

-16M

Ventes

245K

245K

BPA

-0.27

Marge bénéficiaire

-6,465.066

Employés

9

EBITDA

-703K

-15M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+99.25% upside

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

37M

398M

Ouverture précédente

74.83

Clôture précédente

1.4

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Aldeyra Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 nov. 2024, 20:20 UTC

Principaux Mouvements du Marché

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Comparaison

Variation de prix

Aldeyra Therapeutics Inc prévision

Objectif de Prix

By TipRanks

99.25% hausse

Prévisions sur 12 Mois

Moyen 10.6 USD  99.25%

Haut 12 USD

Bas 10 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

5

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

5.04 / 6.59Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Neutral Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.